Welcome to our dedicated page for Petros Pharmaceuticals news (Ticker: PTPI), a resource for investors and traders seeking the latest updates and insights on Petros Pharmaceuticals stock.
News about Petros Pharmaceuticals, Inc. (PTPI) centers on its efforts to build a technology-driven platform for prescription-to-over-the-counter (Rx-to-OTC) drug switches and its evolving capital markets profile. Company press releases describe Petros’ transition toward a smart healthcare technology model, highlighting development of a proprietary SaaS platform and Software-as-a-Medical-Device (SaMD) web application designed to help pharmaceutical sponsors navigate FDA requirements for nonprescription access.
Readers following PTPI news will see updates on the company’s AI- and big data–enabled platform, including collaborations with a big data and analytics provider and with Innolitics, which Petros identifies as a SaMD developer. These stories discuss enhancements such as identity verification, document authentication, deep fake detection, facial and ID recognition, and machine learning–based auto capture, all intended to support safe and appropriate OTC access to formerly prescription products.
Petros’ news flow also includes regulatory and policy context, with management statements about alignment with FDA’s "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) rules and U.S. executive orders aimed at expanding OTC access and lowering drug prices. The company frequently references the emerging self-care market and its belief that its technology-assisted platform could help pharmaceutical partners pursue Rx-to-OTC switches across multiple indications.
In addition, PTPI news covers corporate and capital markets developments such as a reverse stock split, public offerings of common stock and warrants, and changes in listing status, including suspension and delisting from Nasdaq and transition to OTC trading. Coverage also addresses the deconsolidation and discontinued operations of Metuchen Pharmaceuticals and its subsidiaries, which Petros presents as part of a broader corporate realignment and balance sheet strengthening effort. Investors and observers can use this news stream to track Petros’ technology milestones, regulatory positioning, and key corporate actions over time.
Petros Pharmaceuticals (Nasdaq: PTPI) reported Q3 2021 results, revealing net sales of $2.2 million, down from $3.5 million in Q3 2020. Despite record-level STENDRA® prescriptions and a 46% increase in gross sales from the Prescription Medicines segment, net sales were negatively impacted by higher allowances, including product returns and discounts. Operating expenses rose to $3.6 million, leading to an adjusted EBITDA loss of ($1.9 million). Cash reserves decreased to $8.1 million as of September 30, 2021, down from $17.1 million at year-end 2020.
Petros Pharmaceuticals (Nasdaq: PTPI) will present a corporate overview at the Q4 Investor Summit Conference, held virtually on November 16-17, 2021. President and Chief Commercial Officer Fady Boctor is scheduled to deliver the presentation on November 17 at 1:15 PM ET. He will also be available for one-on-one meetings during the event. Petros aims to be a leader in specialized men’s health therapeutics, focusing on issues such as erectile dysfunction and hormonal health.
Petros Pharmaceuticals (Nasdaq: PTPI) announced an expansion of its program for H100, a non-invasive topical treatment for Peyronie's disease. H100 is designed to alleviate the inflammatory issues causing pain and irregularities in penile shape. Through an exclusive agreement with Hybrid Medical LLC, Petros aims to position H100 as the first approved non-invasive treatment for this condition. The company expresses optimism about H100's potential safety profile and expedited development timeline under a 505(b)(2) submission process.
Petros Pharmaceuticals (PTPI) has reported a remarkable 476% increase in STENDRA tablet sales year-over-year, attributed to its exclusive digital health marketing agreement with Hims & Hers Health. The partnership allows greater consumer access to STENDRA through Hims' telehealth platform, which now offers multiple dosages. Despite the growth, the company faces significant challenges, including reliance on a single product for revenue and the potential for market volatility. With only 25% of men with erectile dysfunction receiving treatment, the market opportunity remains substantial.
Petros Pharmaceuticals (Nasdaq: PTPI) announces participation in two upcoming Benzinga events. President Fady Boctor will be featured in a 20-minute interview at the Benzinga All Access Show on October 22, 2021, discussing corporate developments. Additionally, Boctor will present a corporate overview at the Benzinga Global Small Cap Conference on October 27, with one-on-one meetings available throughout the event. The company aims to lead in specialized men's health therapeutics.
Petros Pharmaceuticals (Nasdaq: PTPI) has closed a registered direct offering, raising approximately $5.7 million from its largest and other existing investors. The funds will support the expansion of its men's health platform and provide working capital. CEO Fady Boctor emphasized that this financing is vital for the continued development of its product STENDRA and other promising assets, particularly following STENDRA's strong market performance in recent quarters.
Petros Pharmaceuticals (Nasdaq: PTPI) announced a registered direct offering, agreeing to sell 3,323,616 shares of common stock at $1.715 per share, expected to generate around $5.7 million before expenses. The funds will be used to expand its men's health platform and for general corporate purposes. Closing is anticipated on or around October 18, 2021. Additionally, unregistered warrants for the same number of shares will be issued. The offering is part of compliance with SEC regulations and aims at enhancing shareholder value.
Petros Pharmaceuticals (Nasdaq: PTPI) announces its participation in the virtual Benzinga Healthcare Small Cap Conference from September 29-30, 2021. President and Chief Commercial Officer Fady Boctor will present on September 30 at 2:40 PM ET and will be available for one-on-one meetings throughout the event. The company is focused on becoming a leading men's health provider by developing innovative therapeutics for various issues, including erectile dysfunction and hormone health.
Petros Pharmaceuticals, a leader in men's health therapeutics, announces that President Fady Boctor will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021. The presentation will be accessible starting at 7:00 AM ET on September 13. Additionally, Mr. Boctor will hold one-on-one meetings throughout the event. Petros Pharmaceuticals aims to be a top specialized men's health company focusing on issues like erectile dysfunction, Peyronie's disease, and hormone health.
Petros Pharmaceuticals (PTPI) reported strong financial performance for Q2 2021, with net sales of $2.5 million, a 79% increase year-over-year. The growth was driven by a 123% rise in STENDRA net sales, contributing $1.7 million, and 28% growth in Medical Device sales. Gross margins reached 84%, up from 61% in Q2 2020. The company is pursuing over-the-counter status for STENDRA and expanding its labeling with FDA. However, cash reserves decreased to $11 million by June 30, 2021.
FAQ
What is the current stock price of Petros Pharmaceuticals (PTPI)?
What is the market cap of Petros Pharmaceuticals (PTPI)?
